This Article Full Text (PDF) Submit a related Letter to the Editor Alert me when this article is cited Alert me when eLetters are posted Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Copyright Permission Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by PIETSCHMANN, P. Articles by SMOLEN, J. Search for Related Content PubMed PubMed Citation Articles by PIETSCHMANN, P. Articles by SMOLEN, J.

Decreased Serum Osteocalcin Levels in Phenprocoumon-Treated Patients

Departments of Internal Medicine II and Internal Medicine I (S.P., P.K.), University of Vienna, and the Ludwig Boltzmann-Institute for Clinical Endocrinology (W.W.) Vienna, Austria

Address all correspondence and requests for reprints to: Dr. P. Pietschmann, Department of Internal Medicine II, University of Vienna, Garnisongasse 13, 1090 Vienna, Austria.

Osteocalcin (OC) is a noncollagenous bone matrix protein containing -carboxyglutamic acid, the synthesis of which is vitamin K dependent. Serum OC levels are generally believed to reflect the de novo synthesis of OC by osteoblasts and thus reflect bone formation. We measured serum OC levels by RIA in 48 patients receiving phenprocoumon anticoagulant treatment, which inhibits the posttranscriptional synthesis of -carboxyglutamic acid, and in 22 matched normal subjects. The median serum OC level in the patients receiving phenprocoumon therapy was significantly lower than that in the normal subjects (P < 0.0001). In 27 patients receiving anticoagulant therapy and in 21 normal subjects the proportion of noncarboxylated OC to total OC also was determined. The proportion of OC that was noncarboxylated was significantly higher in the patients receiving phenprocoumon therapy than in the normal subjects (P < 0.0001). We conclude that OC carboxylation is impaired in patients receiving oral anticoagulant therapy. The decreased total OC levels in patients receiving phenprocoumon treatment might result from decreased bone formation, although these patients do not have symptoms of bone disease.

Received August 11, 1987.

This article has been cited by other articles:

				S. L Booth, A. H Lichtenstein, M. O'Brien-Morse, N. M McKeown, R. J Wood, E. Saltzman, and C. M Gundberg Effects of a hydrogenated form of vitamin K on bone formation and resorption Am. J. Clinical Nutrition, December 1, 2001; 74(6): 783 - 790. [Abstract] [Full Text]

				N. C Binkley, D. C Krueger, J. A Engelke, A. L Foley, and J. W Suttie Vitamin K supplementation reduces serum concentrations of under-{gamma}-carboxylated osteocalcin in healthy young and elderly adults Am. J. Clinical Nutrition, December 1, 2000; 72(6): 1523 - 1528. [Abstract] [Full Text] [PDF]